Luminex Reaches New 52-Week High (LMNX)

NEW YORK ( TheStreet) -- Luminex Corporation (Nasdaq: LMNX) hit a new 52-week high Friday as it is currently trading at $24.75, above its previous 52-week high of $24.70 with 134,613 shares traded as of 1:49 p.m. ET. Average volume has been 248,600 shares over the past 30 days.

Luminex has a market cap of $1.01 billion and is part of the health care sector and health services industry. Shares are up 14.4% year to date as of the close of trading on Thursday.

Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries. The company has a P/E ratio of 70.9, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Luminex as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Luminex Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.